“Biopreservation Market Report is set to have rapid growth due to consistent drug developments, advent of advanced therapies in the field of biomedical research and significant rise in patient base requiring high-end treatment for chronic diseases at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report
04 September 2019
Visiongain has launched a new pharma report Biopreservation Market Report : By Product (Equipment, Media, LIMS), By Application (Regenerative Medicine, Bio-banking, Drug Discovery), By Cell Provider, Regional And Segment Forecasts
The global biopreservation market is poised for rapid growth between 2019 and 2029. The drivers include increasing healthcare expenditure, growing demand for preserving new-born’s stem cells, increasing R&D spending on research, and increasing adoption of regenerative medicine.
An increase in healthcare costs is also expected to improve access to quality health care and advanced products, which include biopreservation facilities, thus expanding growth prospects. In addition, hospitals, gene banks and biobanks, which are significant end users for this market, are encouraging key players to develop technologically advanced biopreservation products to improve patient outcomes.
The presence of government health initiatives that provide funds, grants and research contracts have led to an accelerated growth of research and development activities carried out by various companies. This, in turn, has led to the expansion of the possibility of adopting advanced bioconservation services, which is foreseen for the rate of fuel penetration during the forecast period.
Technological advances in biopreservation processes are also important growth factors that contribute to the market. Advances include the change in the formulation of hypothermic conservation solutions, next-generation cryopreservation solutions and design and integration with nanoscale technologies. These technological updates have led to the conservation and long-term storage of complex organs and tissues of great importance in regenerative medicine and organ transplantation.
Leading companies featured in the report include BioLife Solutions Inc., BioCision, Biomatrica, Chart MVE Biomedical, TissueGene, LabVantage Solutions, Panasonic Biomedical, Qiagen, Taylor-Wharton Cryogenics and Thermo Fisher Scientific
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.
30 November 2020
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.